Clermont, Florida Correspondent — The pattern in the shortages is worth stating plainly, because it isn’t what people assume. The drugs that vanish are almost never the expensive new ones. They’re cheap, old, off-patent sterile injectables — the things that cost four dollars a vial.

That’s an economics problem before it’s a security problem. At four dollars there’s no margin to fund a redundant line, no margin to modernize a plant, and no reason for a third company to enter. So one facility gets a quality finding and a third of the national supply stops.

Resilience needs real visibility into where ingredients and doses are actually made, selective surge capacity for the critical list, and multi-year procurement that gives somebody a reason to maintain capacity. Reshoring everything would raise costs sharply and wouldn’t fix the margin.

Novi, Michigan Correspondent — Map the true sources, keep surge capacity for the highest-priority drugs, and use longer contracts to support it.

This is a procurement design problem and it’s one my industry solved decades ago, imperfectly. You don’t get a resilient supply base by running a reverse auction every year. You get it by paying somebody to be available.

Hospital group purchasing is structured to extract the last penny, and it succeeded. The shortage is the success.

Sydney, Australia Correspondent — Visibility, diversified sourcing, and maintained surge capacity for essentials produce more resilience than attempts at national production.

We face the same shortages, frequently the same molecules, and often for the reason that a small market simply isn’t worth a manufacturer’s registration effort. Australia has had drugs discontinued here because our volume didn’t justify the paperwork.

That suggests something the American debate underrates. Part of the answer is regulatory harmonisation among trusted countries — mutual recognition of inspections and approvals, so that a plant cleared in one jurisdiction can supply another without a duplicate process. That widens everyone’s effective supply base at no capital cost, and it’s the cheapest resilience available.

Sheffield, Jamaica Correspondent — Better visibility, selective surge capacity, and reliable contracts for critical drugs. Full reshoring is unnecessary and expensive.

I would raise a consequence that is invisible from here. When a large purchaser secures its supply through exclusive multi-year arrangements, the residual market becomes thinner and more volatile for everyone else. My region buys from that residual.

I am not arguing against American resilience. I am noting that resilience obtained by contracting the available supply is a transfer rather than a creation, and that the transfer has a direction.

Jacksonville, Florida Correspondent — After the latest shortage of a cheap sterile injectable, the story isn’t a surprise anymore. Single plants, single countries, quality findings, and a purchasing model that chases the last penny until the penny becomes a missing vial.

Dual source on a short list. Multi-year contracts a domestic or allied line can borrow against. Visibility into the actual ingredient address rather than the label. A reserve that isn’t a press release.

We also had the recall situation this autumn on a common heartburn drug, and I’d note what it exposed. Nobody could quickly say which finished products traced back to which ingredient plant. That’s not a stockpile problem. That’s not knowing what you own.

Las Vegas, Nevada Correspondent — Hospitals here already keep informal lists of the drugs that disappear on a holiday weekend. That list is institutional knowledge held by pharmacy directors and it exists in no policy document.

The fix is boring. Second source, a contract that isn’t a spot buy, a modest reserve.

If a company is the only maker of a molecule, treat that molecule like a utility — obligations, notice requirements before exiting a product, not a speech. Don’t nationalize an industry. Do obligate a chokepoint.

Knoxville, Tennessee Correspondent — Rural hospitals feel a shortage first and hardest, because they have no purchasing leverage and no ability to substitute. When a drug is allocated, allocation follows volume, and we don’t have volume.

Federal purchasing and veterans’ system scale can anchor a second line if we stop treating the lowest bid as the only civic virtue.

Price the availability. Publish the source. Inspect the source, including the ones overseas, which we inspect at a fraction of the rate we inspect domestic plants.

Tyler, Texas Correspondent — I write coverage for clinics, and the shortage conversation has changed in my book over about five years. It used to be an occasional call. It’s now a standing operational assumption.

The insurance angle nobody raises: a canceled procedure schedule isn’t a covered loss under any form I sell. The hospital eats it, the patient eats the delay, and it never appears as a cost anywhere, which is exactly why the purchasing side has no reason to price against it.

Cap and time a premium for a second line. Permit the plant. Leave the rest of the drugstore a market.